Elisabeth A. Lasater

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

Christine M. McMahon, Timothy T. Ferng, Jonathan Canaani et al. · Cancer Discovery · 2019 · 437 citations · Full text

Medicine, Oncology, Pharmacology +16

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

Pietro Ciceri, Susanne Müller, Alison O’Mahony et al. · Nature Chemical Biology · 2014 · 350 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Crenolanib is a selective type I pan-FLT3 inhibitor

Catherine C. Smith, Elisabeth A. Lasater, Kimberly C. Lin et al. · Proceedings of the National Academy of Sciences · 2014 · 210 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397

Catherine C. Smith, Chao Zhang, Kimberly C. Lin et al. · Cancer Discovery · 2015 · 203 citations · Full text

Medicine, Medicinal Chemistry, Oncology +13

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

Raghuveer Singh Mali, Qi Zhang, RosaAnna DeFilippis et al. · Haematologica · 2020 · 140 citations · Full text

Medicine, Oncology, Pharmacology +13